TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00757939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: 2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: 2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
Study: NCT00962039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
Study: NCT01847664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV-MMX® 400 mg b.i.d.
Study: NCT00902044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes
Study: NCT01847664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV-MMX® 600 mg t.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rifamycin SV-MMX® Placebo
Study: NCT04514237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 enantiomer E1 or E2
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 enantiomer E1 or E2
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT02114333

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: 0.65ml, subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zostavax
Description: 0.65ml, subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HZ/su vaccine
Description: 0.5ml, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HZ/su vaccine
Description: 0.5ml, intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.65ml, subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.65ml, subcutaneous
Study: NCT01182948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
Study: NCT03259997

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: Probiotic supplement
Study: NCT04484402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: limbal stem cells
Description: Autologous adipose-derived limbal stem cells mixed with sodium hyaluronate 1% solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Standard treatment according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Standard treatment according to the Clinical protocols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Standard treatment according to the Clinical protocols
Study: NCT00902044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered for 5 days prior to the T cells~The dose:~\>10 kg: 25 mg/m2/day;~\<10 kg: 1 mg/kg/day IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered for 2 days.~Fludarabine and cyclophosphamide will be given for 2 days, followed by fludarabine alone for the next 3 days, followed by 2 days of rest, before the T cells will be administered.~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~\>10 kg: 25 mg/m2/day; \<10 kg: 1 mg/kg/day IV over 30 minutes
Study: NCT04361318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Oxygen administered via ventilator. In addition, antipyretic paracetamol may be added if necessary
Study: NCT01918384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-14
Description: NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
Study: NCT03225885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia Information
Description: Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Handout
Description: Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
Study: NCT01419691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auranofin
Description: 6 mg twice a day for a total of 12 mg total daily dose
Study: NCT01786941

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training

Intervention type: OTHER
Group type: OTHER
Intervention: GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery
Study: NCT02015572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational intervention
Description: Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
Study: NCT02302807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Description: Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinflunine
Description: Vinflunine 320 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle.
Study: NCT00570570

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscular Strengthening for paretic knee flexor and extensor
Description: thrice a week during 6 weeks
Study: NCT00902044

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CAR Positive T cells
Description: Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
Study: NCT06379360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypomethylating agent, Azacitidine or Decitabine
Description: All enrolled patients received maintenance therapy consisting of Azacitidine (75mg/m2, subcutaneous injection, days 1-7) or Decitabine (20mg/m2, intravenous infusion, days 1-5), every three months as a cycle, for a maintenance therapy of 4-8 cycles.
Study: NCT01541358

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 sodium fluoride
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan
Study: NCT01956669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib was supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension was a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
Study: NCT04730999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Induction phase: 100 mg/sqm on days 1-3, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction phase: AUC 5 on day 1 for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration. Treatment will continue until progression of disease, unacceptable toxicity, patient refusal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Induction phase: 7.5 mg/kg on day 1, for a maximum of 6 cycles (each one of 21 days duration). Intravenous administration.~Maintenance phase: 7.5 mg/kg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Induction phase: flat dosing of 1200 mg on day 1, for a maximum of 6 cycles ( each one of 21 days duration). Intravenous administration.~Maintenance phase: flat dosing of 1200 mg on day 1, for a maximum of 12 cycles (each one of 21 days duration). Intravenous administration.~In both phases, the treatment will continue until progression of disease, unacceptable toxicity, patient refusal, loss of clinical benefit.
Study: NCT02808442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART19
Study: NCT00882635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance \< 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
Study: NCT02390258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 120mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg XEN-D0103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150mg XEN-D0103
Study: NCT02321813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quality of life pathway
Description: Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
Study: NCT04153292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN M3 valve and dock
Description: During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
Study: NCT02321813

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: Quality of life measurement
Study: NCT04153292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN M3 valve and dock
Description: During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN M3 valve and dock
Description: During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.
Study: NCT02936752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02881125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT04040530

Intervention type: PROCEDURE
Intervention: CT-guided cryoablation
Description: Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.

Intervention type: PROCEDURE
Intervention: Partial nephrectomy
Description: Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
Study: NCT02000999

Intervention type: OTHER
Intervention: brushing of bile duct strictures for cytology
Study: NCT04687085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10 minute mindful meditation recording
Description: 10 minute mindful meditation recording

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 10 minute mindful meditation recording
Description: 10 minute mindful meditation recording
Study: NCT02400151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to this group will receive placebo for 90 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 months lifestyle and dietary management
Description: Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3 months lifestyle and dietary management
Description: Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.

Intervention type: OTHER
Group type: OTHER
Intervention: Normal control
Description: Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
Study: NCT02650596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Liraglutide were taken daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo were taken daily for 3 months
Study: NCT03812354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THRIVE 4L/kg/min
Description: High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE 2L/kg/min
Description: High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher\&Paykel, Auckland, New Zealand.
Study: NCT03259997

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04431154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of HIV self-screen kit with incentives and linkage promotion
Description: This arm will receive a HIV self-screen kit and additional incentives to promote adherence and linkage to care
Study: NCT03591146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC590
Description: TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
Study: NCT05155475

Intervention type: PROCEDURE
Intervention: Ultrasound endoscopy
Description: After identification of the lesion, the common bile duct will be identified and followed by the point of dilation due to the compression of the known lesion up to the hilum of the liver
Study: NCT00446446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
Study: NCT01339949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRay
Description: low voltage external beam radiosurgery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IRay
Description: low voltage external beam radiosurgery
Study: NCT02142894

Intervention type: DEVICE
Intervention: CST001
Study: NCT03085706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBMC autotransplantation
Description: Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
Study: NCT01488318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 150 mg po